Publikationen

2026
Inhibition of RNA polymerase II-activating CDK9 and CDK12/13, but not of cell cycle relevant CDKs, induces apoptosis by downregulating the short-lived Bcl-2 proteins Mcl1 and Bfl1/A1

Krings K S, Hatzfeld J, Weller S, Borkowski N, Llewellyn T R, Schmitt L, Scherer B, Itkonen H M, Peter C, Stork B, Geyh S, Eickhoff J, Klebl B, Qin N, Essmann F and Wesselborg S. Cell Death Dis. 2026; 17 (1): doi: 10.1038/s41419-026-08889-6

An Imidazo[2,1-b][1,3,4]thiadiazole Derivative Inhibits the Virulence Factor alpha-Hemolysin by Blocking the Pullout of Its Stem Domain

Korotkov V S, Lukat P, Di Lucrezia R, Shekhar A, Degenhart C, Diestel R, Bilitewski U, Dinkel K, Blankenfeldt W and Bronstrup M. ChemMedChem. 2026; 21 (4): e202501098. doi: 10.1002/cmdc.202501098

Reducing PI4KIIIalpha Levels or Activity Limits Tau Seed Internalization and Assembly in Human Cortical Neurons

Clemente E, Sivasubramanian R, Kordes S, Bhatia P, Hans R, Vogel S, Baumann M, Klebl B and Sterneckert J. Cells. 2026; 15 (13): doi: 10.3390/cells15131228

Towards selective peptide deformylase inhibitors: A mass spectrometry-based evaluation of in cellulo activity of actinonin and bromoindole derivatives

Bachmann N, Schultz A, Zouatom M, Zhou T, Degenhart C, Koch U, Schakermann S, Huning J, Heinrich S, Dal Molin M, Zischinsky M L, Tourel S, Klebl A K, Rybniker J, Klebl B M, Scherkenbeck J and Bandow J E. Eur J Med Chem. 2026; 308 118678. doi: 10.1016/j.ejmech.2026.118678

Expression of recombinant human glutamylating TTLLs in human cells leads to differential tubulin glutamylation patterns, with only TTLL6 disrupting microtubule dynamics

Al Kabbani M A, Jatoo P, Klebl A K, Klebl B and Zempel H. PLoS One. 2026; 21 (3): e0339922. doi: 10.1371/journal.pone.0339922

2015
Selective inhibitors of the FK506-binding protein 51 by induced fit

Gaali S, Kirschner A, Cuboni S, Hartmann J, Kozany C, Balsevich G, Namendorf C, Fernandez-Vizarra P, Sippel C, Zannas A S, Draenert R, Binder E B, Almeida O F, Ruhter G, Uhr M, Schmidt M V, Touma C, Bracher A, Hausch F. Nat Chem Biol. 2015; 11 (1): 33-37. doi: 10.1038/nchembio.1699

Design, synthesis and decoration of molecular scaffolds for exploitation in the production of alkaloid-like libraris

Craven P, Aimon A, Dow M, Fleury-Bregeot N, Guilleux R, Morgentin R, Roche D, Kalliokoski T, Foster R, Marsden S P, Nelson A. Bioorg Med Chem. 2015; 23 (11): 2629-2635. doi: 10.1016/j.bmc.2014.12.048

Medicinal Chemists of the 21st Century – Who Are We and Where to Go?

Nussbaumer P. ChemMedChem. 2015; 10 (7): 1133-1139. doi: 10.1002/cmdc.201500133

Expansion of Chemical Space for Collaborative Lead Generation and Drug Discovery: The European Lead Factory Perspective

Karawajczyk A, Giordanetto F, Benningshof J, Hamza D, Kalliokoski T, Pouwer K, Morgentin R, Nelson A, Muller G, Piechot A, Tzalis D. Drug Discov Today. 2015; 20 (11): 1310-1316. doi: 10.1016/j.drudis.2015.09.009

Professional translational research: a new hybrid paradigm in early drug discovery

Nussbaumer P, Klebl B. Future Med Chem. 2015; 7 (14): 1879-1889. doi: 10.4155/fmc.15.124

Price-Focused Analysis of Commercially Available Building Blocks for Combinatorial Library Synthesis

Kalliokoski T. ACS Comb Sci. 2015; 17 (10): 600-607. doi: 10.1021/acscombsci.5b00063

Protein-protein interactions as drug targets

Skwarczynska M, Ottmann C. Future Med Chem. 2015; 7 (16): 2195-2219. doi: 10.4155/fmc.15.138

Aminomethylhydroxylation of alkenes: Exploitation in the synthesis of scaffolds for small molecule libraries

Colomer I, Adeniji O, Burslem G M, Craven P, Rasmussen M O, Willaume A, Kalliokoski T, Foster R, Marsden S P, Nelson A. Bioorg Med Chem. 2015; 23 (11): 2736-2740. doi: 10.1016/j.bmc.2015.01.058

A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations

Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeittrager I, Bahsi H, Wagner S, Zischinsky G, Wolf A, Degenhart C, Unger A, Baumann M, Klebl B, Marschall M. Antimicrob Agents Chemother. 2015; 59 (4): 2062-2071. doi: 10.1128/AAC.04534-14